The beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy

Journal of Cardiology

Volumn 62, Issue 2, 2013, Pages 110-116

  Jin, Zhe ^a   Zhang, Jian ^a   Zhi, Huilan ^b   Hong, Bingzhe ^a   Zhang, Shuying ^a   Guo, Huishu ^c   Li, Longhu ^a  

^a DALIAN UNIVERSITY   (China)

^b Dalian Youyi Hospital   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Cardiomyocyte atrophy; Cardiomyopathy; Doxorubicin; Myocardial fibrosis; Tadalafil

Indexed keywords

CYCLIC GMP; DOXORUBICIN; MYOSIN HEAVY CHAIN; TADALAFIL; TROPONIN I;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARDIOMYOPATHY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART WEIGHT; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; SARCOMERE;

CARDIOMYOCYTE ATROPHY; CARDIOMYOPATHY; DOXORUBICIN; MYOCARDIAL FIBROSIS; TADALAFIL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ATROPHY; CARBOLINES; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; CYCLIC GMP; DISEASE MODELS, ANIMAL; DOXORUBICIN; FIBROSIS; MALE; MICE; MICE, INBRED C57BL; MYOCARDIUM; MYOCYTES, CARDIAC; PHOSPHODIESTERASE 5 INHIBITORS; SIGNAL TRANSDUCTION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84880133629     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2013.03.018     Document Type: Article

References (34)

1. Hortobagyi G.N. Anthracyclines in the treatment of cancer. An overview. Drugs 1997, 54(Suppl. 4):1-7.
2. Olson R.D., Mushlin P.S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 1990, 4:3076-3086.
3. Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998, 339:900-905.
4. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56:185-229.
5. Singal P.K., Li T., Kumar D., Danelisen I., Iliskovic N. Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem 2000, 207:77-86.
6. Fu L.X., Waagstein F., Hjalmarson A. A new insight into adriamycin-induced cardiotoxicity. Int J Cardiol 1990, 29:15-20.
7. Arai M., Yoguchi A., Takizawa T., Yokoyama T., Kanda T., Kurabayashi M., Nagai R. Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription. Circ Res 2000, 86:8-14.
8. Rotella D.P. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 2002, 1:674-682.
9. Ahmad N., Wang Y., Ali A.K., Ashraf M. Long-acting phosphodiesterase-5 inhibitor, tadalafil, induces sustained cardioprotection against lethal ischemic injury. Am J Physiol Heart Circ Physiol 2009, 297:H387-H391.
10. Yao A. Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension. J Cardiol 2012, 60:344-349.
11. Salloum F., Yin C., Xi L., Kukreja R.C. Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 2003, 92:595-597.
12. Li L., Haider H.Kh., Wang L., Lu G., Ashraf M. Adenoviral short hairpin RNA therapy targeting phosphodiesterase 5a relieves cardiac remodeling and dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol 2012, 302:H2112-H2121.
13. Koka S., Das A., Zhu S.G., Durrant D., Xi L., Kukreja R.C. Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. J Pharmacol Exp Ther 2010, 334:1023-1030.
14. Abd-Allah A.R., Al-Majed A.A., Mostafa A.M., Al-Shabanah O.A., Din A.G., Nagi M.N. Protective effect of Arabic gum against cardiotoxicity induced by doxorubicin in mice: a possible mechanism of protection. J Biochem Mol Toxicol 2002, 16:254-259.
15. Forgue S.T., Patterson B.E., Bedding A.W., Payne C.D., Phillips D.L., Wrishko R.E., Mitchell M.I. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2006, 61:280-288.
16. Li Y., Takemura G., Kosai K., Yuge K., Nagano S., Esaki M., Goto K., Takahashi T., Hayakawa K., Koda M., Kawase Y., Maruyama R., Okada H., Minatoguchi S., Mizuguchi H., et al. Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice. Circulation 2003, 107:2499-2506.
17. Ito H., Miller S.C., Billingham M.E., Akimoto H., Torti S.V., Wade R., Gahlmann R., Lyons G., Kedes L., Torti F.M. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci USA 1990, 87:4275-4279.
18. Esaki M., Takemura G., Kosai K., Takahashi T., Miyata S., Li L., Goto K., Maruyama R., Okada H., Kanamori H., Ogino A., Ushikoshi H., Minatoguchi S., Fujiwara T., Fujiwara H. Treatment with an adenoviral vector encoding hepatocyte growth factor mitigates established cardiac dysfunction in doxorubicin-induced cardiomyopathy. Am J Physiol Heart Circ Physiol 2008, 294:H1048-H1057.
19. Nojiri A., Hongo K., Kawai M., Komukai K., Sakuma T., Taniguchi I., Yoshimura M. Scoring of late gadolinium enhancement in cardiac magnetic resonance imaging can predict cardiac events in patients with hypertrophic cardiomyopathy. J Cardiol 2011, 58:253-260.
20. Arola O.J., Saraste A., Pulkki K., Kallajoki M., Parvinen M., Voipio-Pulkki L.M. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 2000, 60:1789-1792.
21. Billingham M.E., Mason J.W., Bristow M.R., Daniels J.R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978, 62:865-872.
22. Doroshow J.H., Davies K.J. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J Biol Chem 1986, 261:3068-3074.
23. Myers C.E., McGuire W.P., Liss R.H., Ifrim I., Grotzinger K., Young R.C. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977, 197:165-167.
24. Li L., Takemura G., Li Y., Miyata S., Esaki M., Okada H., Kanamori H., Khai N.C., Maruyama R., Ogino A., Minatoguchi S., Fujiwara T., Fujiwara H. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 2006, 113:535-543.
25. Aries A., Paradis P., Lefebvre C., Schwartz R.J., Nemer M. Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci USA 2004, 101:6975-6980.
26. Das A., Smolenski A., Lohmann S.M., Kukreja R.C. Cyclic GMP-dependent protein kinase Ialpha attenuates necrosis and apoptosis following ischemia/reoxygenation in adult cardiomyocyte. J Biol Chem 2006, 281:38644-38652.
27. Kodani E., Xuan Y.T., Takano H., Shinmura K., Tang X.L., Bolli R. Role of cyclic guanosine monophosphate in late preconditioning in conscious rabbits. Circulation 2002, 105:3046-3052.
28. Tsai E.J., Kass D.A. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther 2009, 122:216-238.
29. Kulkarni S.K., Patil C.S. Phosphodiesterase 5 enzyme and its inhibitors: update on pharmacological and therapeutical aspects. Methods Find Exp Clin Pharmacol 2004, 26:789-799.
30. Das A., Xi L., Kukreja R.C. Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3. Biol Chem 2008, 283:29572-29585.
31. Takimoto E., Champion H.C., Li M., Belardi D., Ren S., Rodriguez E.R., Bedja D., Gabrielson K.L., Wang Y., Kass D.A. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005, 11:214-222.
32. Choi S.H., Choi D.H., Song K.S., Shin K.H., Chun B.G. Zaprinast, an inhibitor of cGMP-selective phosphodiesterases, enhances the secretion of TNF-alpha and IL-1beta and the expression of iNOS and MHC class II molecules in rat microglial cells. J Neurosci Res 2002, 67:411-421.
33. Lee D.I., Vahebi S., Tocchetti C.G., Barouch L.A., Solaro R.J., Takimoto E., Kass D.A. PDE5A suppression of acute β-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation. Basic Res Cardiol 2010, 105:337-347.
34. Luo H., He Z. The significance of TGF-β1 expression in heart hypertrophy and its relation to cAMP and cGMP. Med J Chin PLA 2000, 25:267-269.